IGM Biosciences, Inc.

IGM Biosciences is a clinical-stage biotechnology company focused on developing a new class of antibody medicines for the treatment of cancer, autoimmune and inflammatory diseases. They are pioneering the use of engineered therapeutic IgM antibodies, which have ten binding units compared to the two binding units found in the commonly used IgG antibodies. This unique structure allows for greater binding power and potential for novel therapeutic options.

IGM's proprietary IgM platform has enabled them to create a robust pipeline of product candidates, including Aplitabart, a DR5-targeting IgM antibody for colorectal cancer, and Imvotamab, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins for autoimmune diseases. They have overcome various challenges to create these "super antibodies" and continue to explore new scientific boundaries, developing and delivering these new medicines to treat patients with cancer and autoimmune and inflammatory diseases.

IGM Biosciences provides its employees with a comprehensive benefits package that includes flexible spending accounts (FSAs) or healthcare savings accounts (HSAs), three weeks of paid time off, and five sick days. While the company's website does not explicitly mention flexible work arrangements, it does emphasize the company's commitment to the health and well-being of its employees. This suggests that IGM Biosciences may be open to discussing flexible work arrangements on a case-by-case basis.

IGM Biosciences offers a robust and comprehensive benefits package designed to support employee well-being. This includes generous medical, dental, and vision plans with full premium coverage for employees and dependents, flexible spending accounts, a competitive salary, stock options, annual bonuses, employee stock purchase plans, a matching 401(k) plan, paid time off, sick days, pet insurance, commuting and parking benefits, and EV charging stations.

IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of antibody medicines to treat patients with cancer and autoimmune and inflammatory diseases. Their approach leverages the inherent qualities of the naturally occurring IgM antibody structure, which has ten binding units, to create “super antibodies” with the potential to generate novel therapeutic options and hope for patients.

IGM Biosciences promotes a collaborative, team-oriented environment driven by a passion for advancing science. The company fosters a sense of urgency to develop innovative medicines but values a long-term approach to building a thriving workplace. They encourage growth, learning, and fun, aiming to attract individuals who thrive in a fast-paced setting and share their mission to bring a new class of medicines to the world.

IGM Biosciences is committed to building a diverse, equitable, and inclusive workplace that reflects the world around them. They believe that bringing together a wide range of perspectives and experiences fosters a more innovative and creative environment, ultimately leading to better outcomes for patients. They strive to create a welcoming and supportive work environment for all employees, regardless of race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status, or veteran status. They offer robust benefits, including generous medical, dental, and vision plans, competitive salaries, annual bonus programs, and a dedicated professional development budget.